Organovo Holdings, Inc. (ONVO) Stock Analysis

Organovo Holdings, Inc. (ONVO) Healthcare & Pipeline Overview

Organovo Holdings, Inc. develops 3D human tissues for preclinical drug discovery and development. Its NovoGen Bioprinters fabricate living tissues, offering a platform for predictive drug testing. The company's ExVive tissues aim to improve drug development efficiency within the biotechnology sector.

What Is the Investment Thesis for ONVO?

Organovo Holdings, Inc. presents a unique investment opportunity within the biotechnology sector, driven by its innovative 3D bioprinting technology. The company's ExVive human tissues offer a more predictive preclinical testing platform, potentially reducing drug development costs and timelines. A key value driver is the increasing adoption of 3D tissue models in the pharmaceutical industry, driven by the need for more accurate and reliable preclinical data. The company's gross margin of 100% indicates strong pricing power, but its negative profit margin of -864.1% highlights the need for improved operational efficiency. Upcoming catalysts include potential partnerships with pharmaceutical companies and expansion of its ExVive tissue portfolio. Potential risks include competition from alternative preclinical testing methods and the need for significant capital investment to scale up production and commercialization.

Based on FMP financials and quantitative analysis

ONVO Key Highlights

Gross margin of 100.0% indicates strong pricing power in its niche market of 3D human tissues.

• Negative profit margin of -864.1% highlights the company's current lack of profitability and need for improved operational efficiency.
• Beta of 1.13 suggests the stock is slightly more volatile than the market.
• The company focuses on developing 3D tissues that recapitulate key aspects of human disease.
• The company's 3D human tissue platform includes its proprietary NovoGen Bioprinters.

Who Are ONVO's Competitors?

ONVO is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance This table mixes two scoring engines — compare a number only with others carrying the same tag.

What Are ONVO's Key Strengths?

Proprietary NovoGen Bioprinting platform.

• ExVive human tissues offer a more predictive preclinical testing platform.
• Strong gross margin of 100.0%.
• Focus on innovative 3D tissue models.

What Are ONVO's Weaknesses?

Negative profit margin of -864.1%.

• Limited number of employees (14).
• Reliance on a small number of products (ExVive liver and kidney tissues).
• Need for significant capital investment to scale up production.

What Could Drive ONVO Stock Higher?

ONVO catalyst: Potential partnerships with pharmaceutical companies to integrate Organovo's 3D tissues into their drug discovery and development pipelines.

• Expansion of ExVive tissue portfolio to include models for other organs and diseases.
• Development of personalized medicine applications using its bioprinting technology.
• Geographic expansion to new markets, such as Europe and Asia.

What Are the Key Risks for ONVO?

Negative return on equity (-15.6%) — the business is not currently generating profit on shareholder capital.

• Inconsistent delivery — missed Wall Street EPS estimates in 4 of the last 8 reported quarters.
• Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
• Competition from traditional 2D cell cultures and animal models.
• Stringent regulatory requirements for preclinical testing.
• Technological obsolescence.
• Dependence on a limited number of customers.
• Need for significant capital investment to scale up production and commercialization.

What Are the Growth Opportunities for ONVO?

• Expansion of ExVive Tissue Portfolio: Organovo can expand its portfolio of ExVive tissues to include models for other organs and diseases, such as the heart, lung, and brain. The market for 3D tissue models is estimated to reach $1.8 billion by 2027, offering a significant growth opportunity. Timeline: Ongoing.
• Partnerships with Pharmaceutical Companies: Collaborating with pharmaceutical companies to integrate Organovo's 3D tissues into their drug discovery and development pipelines can drive revenue growth. The pharmaceutical industry spends billions of dollars annually on preclinical testing, creating a large potential market for Organovo's products. Timeline: Ongoing.
• Development of Personalized Medicine Applications: Leveraging its bioprinting technology to create patient-specific tissues for drug screening and therapeutic applications can open up new markets. The personalized medicine market is expected to reach $2.4 billion by 2028, driven by advances in genomics and proteomics. Timeline: Ongoing.
• Geographic Expansion: Expanding its sales and marketing efforts to new geographic markets, such as Europe and Asia, can drive revenue growth. The global market for preclinical testing is growing, with significant opportunities in emerging markets. Timeline: Ongoing.
• Development of Therapeutic Tissues: Organovo can leverage its bioprinting technology to develop therapeutic tissues for regenerative medicine applications, such as liver repair and kidney regeneration. The regenerative medicine market is expected to reach $55 billion by 2030, driven by the increasing prevalence of chronic diseases and the aging population. Timeline: Ongoing.

What Are ONVO's Competitive Advantages?

• Proprietary NovoGen Bioprinting platform.
• Expertise in bioprinting complex, functional human tissues.
• Established relationships with pharmaceutical companies.
• High barriers to entry due to the complexity of the technology.

What Does ONVO Do?

Organovo Holdings, Inc., founded in 2007 and headquartered in Solana Beach, California, is a biotechnology company focused on creating functional, three-dimensional human tissues for medical research and therapeutic applications. The company's core technology revolves around its NovoGen Bioprinting platform, which uses automated devices to construct 3D living tissues from mammalian cells. This platform includes proprietary technologies for preparing bio-inks and bioprinting multicellular tissues with complex architectures, mimicking the structure and function of native human tissues. Organovo's primary products are its ExVive human liver and kidney tissues, which are used by pharmaceutical companies and research institutions for preclinical drug testing. These 3D tissues offer a more predictive and physiologically relevant model compared to traditional 2D cell cultures or animal models, potentially reducing the cost and time associated with drug development. By providing more accurate preclinical data, Organovo aims to improve the success rate of clinical trials and accelerate the development of new therapies. The company's technology has the potential to revolutionize drug discovery and personalized medicine by providing a platform for creating patient-specific tissues for research and therapeutic applications.

What Products and Services Does ONVO Offer?

• Develops 3D human tissues for medical research.
• Offers ExVive human liver and kidney tissues for preclinical drug testing.
• Utilizes NovoGen Bioprinters to fabricate living tissues.
• Provides a platform for predictive drug testing.
• Aims to improve drug development efficiency.
• Creates bio-inks for bioprinting multicellular tissues.

How Does ONVO Make Money?

• Generates revenue through the sale of ExVive human liver and kidney tissues.
• Partners with pharmaceutical companies for preclinical drug testing.
• Offers custom tissue development services.
• Focuses on providing more predictive and physiologically relevant models compared to traditional methods.

What Industry Does ONVO Operate In?

Organovo operates within the biotechnology industry, which is characterized by rapid innovation, high R&D costs, and stringent regulatory requirements. The market for preclinical drug testing is growing, driven by the increasing demand for more accurate and predictive models. Organovo's 3D human tissues compete with traditional 2D cell cultures, animal models, and other emerging technologies. The company's competitive advantage lies in its proprietary NovoGen Bioprinting platform and its ability to create complex, functional human tissues. The biotechnology industry is expected to continue to grow, driven by advances in genomics, proteomics, and personalized medicine.

Who Are ONVO's Key Customers?

• Pharmaceutical companies.
• Research institutions.
• Drug discovery organizations.
• Academic medical centers.

The most recent 11 insider filings for Organovo Holdings, Inc. break down as 0 sales and 11 purchases. On net that is roughly 895K shares acquired (about $386K) — insiders putting money in tends to read as conviction.

Wall Street analysts project Organovo Holdings, Inc. revenue of about $201K for fiscal 2026, with EPS near $-9.00.

Organovo Holdings, Inc. has missed Wall Street's EPS estimate in 4 of its last 8 reported quarters — a mixed record worth weighing. Reported results have landed about 254.6% below estimates on average.

Organovo Holdings, Inc.'s Piotroski F-Score is 1/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.

Return on equity for Organovo Holdings, Inc. stands at -15.6%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -17.6%, showing how much profit it generates from its asset base. A current ratio of 2.44 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -79.8%, the inverse of the P/E and a quick read on earnings relative to price.

Organovo Holdings, Inc. (ONVO) Valuation Context

Valued at $3.67M, ONVO is classified as a micro-cap stock.

ONVO Revenue & Earnings Trend

In Jun 2026, ONVO generated $18K in top-line revenue, marking a sequential decrease of 55.0%. The company recorded a net loss of $1.3M, with diluted EPS of $-0.26. Quarter-over-quarter revenue has been mixed, typical for a micro-cap company operating in Healthcare. Across the four most recent quarters, ONVO averaged $-1.12 in diluted EPS.

Company Profile

Organovo Holdings, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Solana Beach, US. The company is led by CEO Keith E. Murphy. ONVO has traded publicly since 2012.

ONVO Financials

ONVO Latest News

ONVO Healthcare Stock FAQ

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources